Successful valganciclovir treatment initiated beyond 60 days of age in a preterm infant with congenital cytomegalovirus disease

Pediatr Int. 2024 Jan-Dec;66(1):e15755. doi: 10.1111/ped.15755.

Authors

Aya Okahashi¹, Midori Hijikata¹, Ayako Seimiya¹, Nobuhiko Nagano¹, Harumasa Yokota², Yusuke Kimura³, Ichiro Morioka¹

Affiliations

¹ Department of Pediatrics and Child Health, Nihon University School of Medicine, Tokyo, Japan.
² Department of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
³ Department of Otorhinolaryngology, Nihon University School of Medicine, Tokyo, Japan.

PMID: 38563289
DOI: 10.1111/ped.15755

No abstract available

Keywords: chorioretinitis; development; hearing impairment; neonatal period; ventricular dilatation.

MeSH terms

Antiviral Agents / therapeutic use
Cytomegalovirus
Cytomegalovirus Infections* / congenital
Cytomegalovirus Infections* / diagnosis
Cytomegalovirus Infections* / drug therapy
Hearing Loss, Sensorineural*
Humans
Infant
Infant, Newborn
Infant, Newborn, Diseases*
Infant, Premature
Valganciclovir / therapeutic use

Substances

Valganciclovir
Antiviral Agents

Grants and funding